Liver Testing Through a New Investigative Tool
Liver Function Tests
Breaking Through Conventional Thinking About Liver Health Testing
HepQuant is a privately-held, early-stage medical diagnostics company with unique, patented and patent-pending technology for assessing liver function of patients with chronic liver disease. HepQuant technologies, licensed from the University of Colorado Denver (UCD), have been advanced with the intent to profoundly impact the liver disease landscape – including the research, treatment and patient communities – with diagnostic products that are accurate and minimally invasive.
Liver Testing for Pharma Trials, Liver Research Trials
Through its Investigational Device Exemption (IDE), HepQuant provides liver testing support services to liver research centers and pharmaceutical companies. The HepQuant tests are designed to evaluate the liver — and levels of hepatic impairment — regardless of the etiology of the liver disease. Specifically, the tests establish a Disease Severity Index score by measuring hepatic blood flow, portal blood flow, and portal-systemic shunt in patients suffering from chronic liver disease (CLD).
Recent News
- June 2 – Tackling Liver Disease with a Multimodal Cyclophilin Inhibitor | pharma’s almanac
- May 24 – Preliminary data from the HepQuant SHUNT-V Pivotal study presented at DDW® 2022
- May 10 – Chris Jensen Joins Business Advisory Board
- May 5 – Bobbi Coffin Named to Business Advisory Board
- May 3 – Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial
- Mar. 24 – Statins Show Promise for Advanced Liver Failure and Cirrhosis | Gastroenterology & Endoscopy News
- Feb. 1 – Pharma and Medical Device Veteran Ally Xu Named Director of Regulatory and Quality Affairs
- Nov. 16 – Preliminary data from the HepQuant SHUNT-V Pivotal study released during the 72nd AASLD Annual Meeting
- Nov. 1 – Perspectum and HepQuant Announce Partnership to Bring a More Complete Picture of Liver Health
Recent Publications
- How clinicians may use tests of hepatic function now and in the future | T. Tara Ghaziani, Paul Y. Kwo | Translational Research (formerly The Journal of Laboratory and Clinical Medicine) | July 1, 2021
- HepQuant SHUNT Detects Portal Hypertension in Early Stages of Clinically Compensated Chronic Liver Disease | Amanda Wieland, Ohad Etzion, Rabab O Ali, Elliot Levy, David E Kleiner, Steve M Helmke, Theo Heller, Gregory T Everson | Clinical Gastroenterology and Hepatology 2021 | April 22, 2021
The HepQuant Story | Where We’ve Been, Where We’re Going
Upcoming Events
♦ The American College of Clinical Pharmacology® (ACCP) Annual Meeting, Sept 25-27th in Bethesda, MD | Abstract submitted: Advantages of HepQuant SHUNT over Child-Pugh Classification in Defining the Pharmacokinetics of Drug Therapy: Experience in a Phase 1 Study of Ampreloxetine in Subjects with Hepatic Impairment
♦ AASLD – The Liver Meeting 2022 | | Washington, DC | November 4-8
Recent Events
♦ EASL International Liver Congress™ 2022 | June 22–26, 2022 | Poster: A multi-compartmental model of the HepQuant SHUNT test quantifies anatomic shunting and stratifies risk for varices: combined results from the HALT-C and SHUNT-V studies
♦ Digestive Disease Week | May 21 – 24, 2022 | HepQuant abstracts accepted:
- The HepQuant’s Disease Severity Index (HepQuant DSI™) Outperforms Child-Pugh (CP) Classification in Quantifying Hepatic Impairment for Prediction of Drug Pharmacokinetics (PK) in Chronic Liver Disease (Poster)
- The HepQuant Shunt Disease Severity Index (HepQuant DSI™) Can Aid the Decision to Avoid Endoscopic Screening or Surveillance for Varices Needing Treatment (Poster)
♦ 40th Annual J.P. Morgan HealthCare Conference | January 10 – 13, 2022 | San Francisco, CA
♦ NASH-TAG Conference | January 6 – 8, 2022
- Poster Presentation: HMG-CoA Reductase Inhibitors (Statins) and Metformin are Associated With Preservation of Hepatic Function and Less Portal-Systemic Shunting in Advanced Chronic Liver Disease (CLD)
♦ NASH Summit 2021 | November 29-December 2 | Sponsor
- Oral Presentation: HepQuant: Progressing towards a Sensitive and Reliable Endpoint for Treatment Efficacy. Greg Everson, MD.
- New Data from Clinical Trials (response to new pharma therapy, reproducibility, progression to decomp in cirrhosis, portal hypertension)
- Pivotal Study and Regulatory Progress
- Anticipated Timelines for Clinical Trial and Commercial Scale-up
♦ AASLD The Liver Meeting | November 12-15
- Poster: BI 685509 Improves Hepatic Function in Subjects with Child-Pugh A Cirrhosis and a Liver Stiffness Measurement of >15 KPA: Results from the HepQuant SHUNT Test. Lawitz EJ, Ertle J, Schoelch C, Gawshaw I, Helmke SM and Everson GT. – (Poster Presentation at AASLD, The Liver Meeting 2021) {Lawitz et al: Hepatology 2021, Volume 74, Number 1 (Suppl), 1238A-1239A}
- Poster: The HepQuant SHUNT Test Predicts the Likelihood of Finding Esophageal Varices and Particularly Large Varices at Endoscopy. Shiffman ML, Leise MD, Reddy KR, Hellstern PA, Hassanein T, Qureshi K, Mena E, Smith AD, Kittelson JM, Helmke SM, Everson GT, HepQuant, and SHUNT-V Investigators Group. {Shiffman et al: Hepatology 2021, Volume 74, Number 1 (Suppl), 1264A-1265A}
- Oral Presentation: Treatment with HMG-CoA Reductase Inhibitors (Statins) is Associated with Preservation of Hepatic Function in Advanced Chronic Liver Disease (CLD): Results from the SHUNT-V Study. Rahimi RS, Lucas KJ, Weinberg EM, Kayali Z, Bhagat VK, Keaveny AP, Mantry PS, Smith AD, Kittelson JM, Helmke SM, Everson GT, and SHUNT-V Investigators Group. {Rahimi et al: Hepatology 2021, Volume 74, Number 1 (Suppl), 98A-99A}
♦ American Heart Association (AHA) Annual Meeting | November 13-15
- Oral Presentation: Clinical and Laboratory Correlates of Impaired Cholate Clearance in the Adult Fontan. Kim YY, Saef J, Everson G, Helmke S, Carducci J, Glatz AC, Partington SL, Ruckdeschel E, Rychik J, Hoteit MA. {Kim et al: Circulation 2021 Volume 144, Suppl_1, A14429} (See Abstract)
CONTACT US
These images and links are for informational purposes only and do not imply that HepQuant has any formal relationships with the organizations, nor do the organizations endorse HepQuant or its liver function tests.